新冠肺炎和 Aerogen

降低患者产生的传染性气溶胶的传播。

最新的 GOLD Report 1 指出,对于接受通气支持的新冠肺炎患者而言…

…保持回路完整,防止病毒的传播至关重要。网状雾化器可以轻松为通气患者添加药物,而无需因输送气雾剂而切断回路.../i>

Aerogen 是唯一的闭路气雾剂给药系统,能减少雾化治疗时患者产生的传染性气雾剂2-7传播并提供有效的治疗。2,8,9

了解 Aerogen 振动网技术如何有效地为新冠肺炎患者提供吸入治疗,并能确保患者和护理人员的安全。

已经发表的国际指南概述了振动网技术在新冠肺炎患者治疗中的应用。1,4,6,10,11

Aerogen 是您为新冠肺炎患者输送吸入性药物的优秀解决方案。

安全

Aerogen 是唯一的闭路气雾剂给药系统,能减少雾化治疗时患者产生的传染性气雾剂扩散并提供有效的治疗。2-7

有效。

Aerogen 能有效地提供吸入药物,2,8,9与喷射雾化器相比,其向肺部8输送的药物多了 5 倍。9

值得信赖

许多世界领先的机械通气公司都推荐使用 Aerogen,包括 Dräger、GE、Hamilton Medical、Maquet、Medtronic 和 Philips。

新冠肺炎相关问题咨询。

无论您身处何方,Aerogen 团队和我们的代表都可以回答您的问题,提供在线演示并下订单。

我们能提供什么帮助?

值得信赖

目前,Aerogen 正与多家公司携手开发针对新冠肺炎的疗法和疫苗5。 Aerogen 技术已经在全球 75 个国家/地区使用了 20 多年,200 多项同行评审研究曾提及此技术5。Aerogen 得到了世界上诸多领先的通气提供商的信任和倾情推荐:


参考文献。

1 DMG Halpin , GJ Criner, A Papi, D Singh , A Anzueto , FJ Martinez, AA Agusti , CF Vogelmeier on behalf of the GOLD Science Committee. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD https://www.atsjournals.org/doi/pdf/10.1164/rccm.202009-3533SO
2 Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987.
3 Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID-19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.
4 Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 17: E020.
5 Aerogen Internal data on file, Aug 2020.
6 Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020; : jamp.2020.1615. 

7 O’Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. Aerosol Air Qual Res 2020; 20. doi:10.4209/aaqr.2020.04.0176.
8 Dugernier J, Reychler G, Wittebole X, Roeseler J, Depoortere V, Sottiaux T et al. Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized study. Ann Intensive Care 2016; 6: 73.
9 MacIntyre NR, Silver RM, Miller CW, Schuler F, Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985; 13: 81–84.
10 Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, Egea Santaolalla C, Masa Jiménez JF, García Fernández J et al. Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. Med Intensiva (English Ed 2020; 44: 429–438.
11 Swarnakar R, Gupta N, Halder I, Khilnani G. ICS guidance for nebulization during the COVID-19 pandemic. Lung India 2020; 0: 0.
12 https://www.aarc.org/wp-content/uploads/2020/03/guidance-document-SARS-COVID19.pdf (accessed 13 Nov2020).